Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | OTC | P00480 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18063326 | 1.00 | MEN1 (0.33) | MEN1GAAKMT2ACYP2D6CYP2C19 | |
| SCHEMBL18063330 | 1.00 | MEN1 (0.33) | MEN1GAAKMT2ACYP2D6CYP2C19 | |
| SCHEMBL20358313 | 0.94 | FOLH1 (0.34) | MEN1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL25224563 | 0.94 | FOLH1 (0.34) | MEN1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL18063334 | 0.88 | CYP2D6 (0.33) | CYP2D6CYP2C19 | |
| SCHEMBL17112231 | 0.88 | CYP2D6 (0.33) | CYP2D6CYP2C19 | |
| SCHEMBL20494573 | 0.82 | ALOX5 (0.41) | MEN1GAAKMT2ACYP2D6CYP2C19 | |
| SCHEMBL18063338 | 0.82 | ALOX5 (0.41) | MEN1GAAKMT2ACYP2D6CYP2C19 | |
| SCHEMBL18063364 | 0.82 | ALOX5 (0.41) | MEN1GAAKMT2ACYP2D6CYP2C19 | |
| SCHEMBL5148636 | 0.81 | PTPN1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-12-27 | — | — | US | disclosed |
| US-20210300944-A1 | FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-09-30 | — | — | US | disclosed |
| EP-3813827-A1 | FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2021-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | STING1, CGAS, MAVS | MEN1 504/4885GAA 169/4885KMT2A 4735/4885 |
| US-20210300944-A1 | FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF | STING1, CGAS, MAVS | MEN1 504/4885GAA 169/4885KMT2A 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.